Stone House Investment Management LLC Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Stone House Investment Management LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, HoldingsChannel reports. The fund purchased 100 shares of the company’s stock, valued at approximately $33,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. DT Investment Partners LLC bought a new position in Medpace during the 2nd quarter worth approximately $41,000. Ashton Thomas Securities LLC acquired a new stake in shares of Medpace during the 3rd quarter valued at approximately $37,000. Ashton Thomas Private Wealth LLC bought a new position in Medpace during the second quarter worth $52,000. Capital Performance Advisors LLP bought a new position in Medpace during the third quarter worth $46,000. Finally, International Assets Investment Management LLC acquired a new position in Medpace in the second quarter worth $61,000. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of Medpace stock traded up $0.94 during midday trading on Wednesday, hitting $336.15. The company had a trading volume of 30,714 shares, compared to its average volume of 283,946. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77. The business’s 50 day simple moving average is $339.37 and its two-hundred day simple moving average is $372.21. The stock has a market cap of $10.45 billion, a PE ratio of 29.35, a P/E/G ratio of 1.87 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. The company had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the firm earned $2.22 EPS. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Robert W. Baird raised their target price on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a report on Monday. Redburn Atlantic began coverage on Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and an average target price of $380.56.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.